- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Lexapro
Synonyms :
escitalopram
Class :
Antidepressants and antianxiety drugs; Selective Serotonin Reuptake Inhibitors
Dosage Forms & Strengths
Tablet
5mg
10mg
20mg
Oral solution
5mg/5 ml
Indicated for the treatment of acute and maintenance
10 mg orally each day
Increase the dose upto 20 mg/day after a week
(Off-Label)
10 mg orally each day
Increase the dose to 20 mg/day after a week
Maintain the lowest effective dose
Assess the need for extended therapy if required
(Off-Label)
After depression- 5-20 mg orally for 8 weeks
After panic disorder- 5-10 mg for 8 weeks
(Off-Label)
After depression- 5-20 mg orally for 8 weeks
After panic disorder- 5-10 mg for 8 weeks
For more than 12 years- 10 mg orally each day
Increase the dose 3 weeks later
Do not exceed more than 20 mg/day
Dosage Forms & Strengths
Tablet
5mg
10mg
20mg
Oral solution
5mg/5 ml
25-50 mg orally each day for 7 days
Increase the dose by 25 mg/day every week
Do not exceed the dose of more than 200 mg orally each day
Dose Modifications
For mild to severe hepatic impairment, 10 mg/day
Dosage Forms & Strengths
Tablet
5mg
10mg
20mg
Oral solution
5mg/5 ml
Major Depressive Disorder
10 mg orally each day
No add-on benefits are seen with 20 mg/day
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the tachycardic effect of Alpha-/Beta-Agonists
antiplatelet agents increase the effect of abrocitinib
it increases the toxicity of SSRIs
it increases the antiplatelet impact of escitalopram
it increases the effect of serotonergic agents
QT-prolongers increase the QTc prolongation of levoketoconazole
it increases the effect of SSRIs
they increase the effect of SSRIs
they increase the effect of SSRIs
they increase the effect of SSRIs
they increase the effect of SSRIs
they increase the effect of SSRIs
it increases the QTc prolongation of QT-prolonging agents
it increases the effect of SSRIs
it increases the QTc prolongation of QT-prolonging agents
may have an increased risk of adverse effects when combined with tropicamide
May increase the hypoglycemic effect of each other when combined
QTc interval is increased both by lenvatinib and escitalopram
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
CYP3A strong enhancers of the small intestine may reduce the bioavailability of escitalopram
May have an increased serotonergic effect when combined with Serotonin/Nore